Montefiore Einstein Joined RECAST Clinical Trial

The center is testing non-surgical treatment options for early-stage breast cancer patients.

Updated on Oct. 7, 2026 in Cancer

A sterile medical examination room featuring a high-tech MRI scanner coil on an examination table. — The Montefiore Einstein Comprehensive Cancer Center has joined the RECAST clinical trial to explore non-surgical treatment options for early-stage breast cancer patients. AI Illustration. Upload story photo >

Live Poll

Do you trust medical approaches that prioritize monitoring over immediate surgery for early-stage cancer conditions?

The Montefiore Einstein Comprehensive Cancer Center has joined the RECAST clinical trial to evaluate alternatives to immediate surgery for ductal carcinoma in situ (DCIS). This research assesses whether medication and monitoring can effectively manage the condition.

Why it matters

Researchers are working to identify which stage zero breast cancer cases can be safely managed without the physical and psychological toll of immediate surgical intervention.

The study targets 400 total participants across 20 nationwide locations. Patients are randomly assigned to one of four unique medical treatment approaches while being monitored via specialized MRIs.

The players

Montefiore Einstein Comprehensive Cancer Center

This is a nationally recognized medical institution that provides advanced cancer care and conducts innovative research.

I-SPY research network

This is a collaborative platform dedicated to accelerating the development of more effective and less toxic breast cancer treatments.

The details

Participants diagnosed with estrogen receptor-positive DCIS undergo an initial MRI before being assigned to a treatment arm that replaces immediate surgery with medication and regular follow-up scans. If MRIs indicate disease progression during the study period, patients move to surgery as a corrective measure.

The Montefiore Einstein site began its participation in October 2026.
Patients receive follow-up MRIs at three months and six months into the trial.
The clinical trial is expected to continue for two to three years.

The Big Picture

This study follows the investigative framework established by the COMET trial regarding DCIS treatment strategies. It extends the research goals previously set by the COMET trial by further refining how clinicians manage DCIS without immediate surgery.

Patients who qualify for this trial may avoid the necessity of immediate surgery, opting instead for medication and rigorous MRI monitoring. Individuals should consult with their oncology team to determine if their diagnosis fits the specific requirements for this study.

The takeaway

This trial represents a shift toward personalized medicine that aims to spare patients unnecessary procedures for non-invasive conditions. Participants benefit from specialized monitoring that ensures disease progression is caught early while maintaining quality of life.